Project title: Leveraging Digital Twin and Gut-on-a-Chip Models for Precision Metformin Dosing in Type 2 Diabetes Patients (DIGI-MET2D)

Project No.: 1.1.1.3/1./24/A/043

Period: 1st May 2025 – 30 April 2028

Project costs: 656 455 EUR

Principal Investigator: Dr. biol. Ilze Elbere

The core objective of DIGI-MET2D is to address an urgent unmet need to improve outcomes for patients with type 2 diabetes (T2D) – to establish a versatile framework for personalised medicine, focusing on T2D treatment through the integration of clinical observations, metagenomic analyses, digital twin simulations, and organ-on-a-chip (GoC) technology. Thus, we will support effective and more efficient use of existing pharmaceutical therapies.

Facing the challenge of Type 2 Diabetes (T2D) in Europe, where 61.4 million adults are affected with a projected increase, our project seeks to revolutionise metformin treatment through personalised medicine. Metformin, the first-line treatment for T2D, shows variable efficacy and side effects, partly due to individual differences in gut microbiota. Recognizing the unmet need for tailored therapies, we propose this project with the following main aim: To establish a versatile framework for personalised medicine, focusing on Type 2 Diabetes (T2D) treatment through the integration of clinical observations, metagenomic analyses, digital twin (DT) simulations, and organ-on-a-chip (GoC) technology.

Information published 06.05.2025.